People
Based in Santa Clara, California, CBT Pharma was spun out of Crown Bioscience with four development-stage assets in the oncology space.
The COO of Seattle Genetics, Eric Dobmeier, is leaving the company to helm Silverback Therapeutics.
There’s been a major shakeup in the executive team at Human Longevity.
There are some changes taking place in the C-suites at Shire.
The company’s head of Development, Joerg Moeller, is taking the reins of the company’s new R&D program.
Ms. Kinjerski is a senior business development executive with more than 17 years of experience in the biopharmaceutical industry,
Since taking over at Teva earlier this fall, Kare Schultz has been swiftly moving to shore up the finances and pay down the massive debts of the beleaguered pharmaceutical company.
Shawver, a long-time industry veteran, will assume the role of president, CEO and director of Synthorx.
Mr. Hartman overviewed the Company’s Anti-Cancer R&D program and discussed his intent to find a licensee for the technology or investment partner to complete the development of this very promising anti-cancer antibody drug.
PRESS RELEASES